Clinical Studies - Follow-Up Only

The following are clinical studies for which enrollment is complete, but follow-up study continues. For "Current Enrollments", click here.

CORAL:  This study looks at patients with renal artery stenosis and randomizes them to either have their renal artery opened by implanting a stent and receiving optimal medical therapy or receiving optimal medical therapy only.  Previous studies have shown conflicting conclusions as to the risk/benefit ratio for renal artery stenting procedures.  For more information, contact Rita at (309) 691-4410.

CHOICE:  This is a registry to collect information and evaluate outcomes of patients who undergo stenting of a blocked carotid artery because they are high risk for the standard of care, which is carotid endarterectomy surgery.  For more information, contact Marsha at (309) 691-4410.

DURABILITY II:  The Protégé^® EverFlex™ Nitinol Stent is used to open blockages in the superficial femoral and proximal popliteal arteries of the legs.  Data is collected on patients who receive this stent for up to three years.  For more information, contact Rita at (309) 691-4410.

EDUCATE:  A prospective multicenter trial to better understand the safety and efficacy of 12 months versus 30 months of dual antiplatelet therapy and relationship to compliance and therapy interruptions in subjects undergoing stenting procedure with Endeavor® Zotarolimus Eluting Coronary Stent System.  For more information, contact Rita at (309) 691-4410.

IMPROVE IT:  A clinical trial to establish the benefit and safety of Vytorin (a combination drug with zocor and zetia) versus zocor monotherapy.  This trial is for patients who have had an acute coronary syndrome event and are high risk for repeat cardiovascular events.  For more information, contact Becky at (309) 691-4410.

REVEAL TIMI 55:  An international study coordinated by University of Oxford compares anacetrapib 100mg once daily versus matching placebo in participants with pre-existing atherosclerotic vascular disease who are also receiving effective LDL-lowering therapy using atorvastatin.  The aims are to assess the effect of anacetrapib on the composite outcome of Major Coronary Events, defined as coronary death, myocardial infarction or coronary revascularization and the effect of anacetrapib on coronary death or myocardial infarction.  For more information, contact Rita at (309) 691-4410.

SOLID TIMI 52:  A multicenter trial to evaluate efficacy of long term treatment with darapladib tablets as compared to placebo when added to standard of care in an acute coronary syndrome patient population on the incidence of first occurrence of the composite of major adverse cardiovascular events.  For more information, contact Gina at (309) 691-4410.

STICH:  For patients who have coronary artery disease that is suitable for bypass surgery, but also have symptomatic congestive heart failure, this study is stratified three ways.  1.  Medical treatment vs. CABG only.  2.  Medical treatment only vs. CABG vs. CABG + SVR.  3. CABG vs. CABG + SVR.  For more information, contact Marsha at (309) 691-4410.

TOPCAT:  A study to determine if the drug spironolactone, in addition to standard therapies, can reduce cardiovascular events and hospitalizations in patients with preserved heart function and congestive heart failure.  For more information, contact Gina at (309) 691-4410.

XIENCE:  A prospective multicenter trial to better understand the safety and efficacy of 12 months versus 30 months of dual antiplatelet therapy and relationship to compliance and therapy interruptions in subjects undergoing stenting procedure with XIENCE V^® Everolimus Eluting Coronary Stent System.  For more information contact, Gina at (309) 691-4410.